A critical health issue has emerged, impacting patients taking GLP-1 drugs like Ozempic. Doctors are now facing a dilemma: should they delay surgeries for these patients due to increased risks? Let's dive into this controversial topic and explore the potential consequences.
The GLP-1 Dilemma: A Growing Concern
GLP-1 agonists, such as Ozempic, have gained popularity for their ability to mimic natural hormones, aiding in weight loss and managing type 2 diabetes. However, their impact on digestion has raised concerns among anesthetists.
David Story, president of the Australian and New Zealand College of Anaesthetists (ANZCA), warns that these drugs can slow digestion, potentially leading to pulmonary aspiration during surgery. This is a serious issue, as it can result in life-threatening complications.
The Risk of Pulmonary Aspiration
Pulmonary aspiration occurs when stomach contents are regurgitated and breathed into the lungs or trachea. This can cause airway obstruction, chemical or physical lung injury, and even lead to ICU admission or, in severe cases, death.
Why Patients Aren't Disclosing Their Medication
Professor Story highlights that patients may arrive for surgery without disclosing their GLP-1 medication for various reasons: forgetfulness, lack of awareness, unsupervised use, or embarrassment about weight loss drugs. This lack of disclosure poses a challenge for anesthetists, who need to be aware of all medications to ensure patient safety.
The Solution: Delay or Proceed?
Anesthetists are taking proactive measures. In some cases, they choose to delay surgery, allowing patients to fast on clear fluids for an additional 24 hours. This extra fasting time ensures the stomach is empty, reducing the risk of aspiration.
However, the decision to delay is not taken lightly. Dr. Vida Viliunas, president of the Australian Society of Anaesthetists, emphasizes that the benefits of GLP-1s often outweigh the risks. She states, "Surgery can either proceed, be deferred, or cancelled. I have techniques to mitigate the risk."
New Guidelines for Patient Safety
ANZCA has updated its guidelines, recommending that anesthetists specifically inquire about GLP-1 medication use. Additionally, patients on GLP-1 drugs are advised to fast on clear fluids for 24 hours, followed by a standard six-hour fast before surgery.
The college acknowledges that the evidence supporting GLP-1s increasing pulmonary aspiration risk is limited. Still, these guidelines represent a consensus based on available evidence and expert opinion.
The Importance of Patient Awareness
Professor Story encourages patients to be mindful of the potential risks and disclose their GLP-1 medication early. He states, "We hope that as people become more aware, they'll think of these medications and tell us early so we can ensure the safest pathway to their surgery."
Ozempic-like medications have gained popularity for weight loss and treating type 2 diabetes, endorsed by the World Health Organization as long-term obesity treatments.
According to preliminary research from New South Wales University, an estimated 500,000 people in Australia are on GLP-1 medications.
Elif Ekinci, director of the Australian Centre for Accelerating Diabetes Innovations, stresses the importance of patients continuing their GLP-1 treatment unless advised otherwise by a doctor. High blood sugar levels can also interfere with surgeries, leading to potential delays or cancellations.
A Call for Honesty
All doctors emphasize the importance of honesty between patients and healthcare practitioners. Professor Story assures, "We as doctors won't judge them. It's crucial for their safety, and that's our role as doctors—to work with them and optimize their care."
This issue highlights the complex balance between the benefits and risks of GLP-1 drugs. As research continues, it's essential for patients and healthcare professionals to stay informed and communicate openly to ensure the best possible outcomes.
